MedTrace Logo

Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox

NCT03358498 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2017-11-30

No results posted yet for this study

Summary

Regular blood transfusions are essential for the management of haematological conditions such as β-thalassemia major. As a result, however, patients with these conditions are susceptible to the development of transfusion-dependent iron overload (hemosiderosis or secondary iron overload

Conditions

  • β-thalassemia

Interventions

OTHER

The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It

SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items. .

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-12-01
Completion
2020-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358498 on ClinicalTrials.gov